KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Profit After Tax (2016 - 2025)

Sarepta Therapeutics has reported Profit After Tax over the past 15 years, most recently at -$412.2 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 359.18% year-over-year to -$412.2 million; the TTM value through Dec 2025 reached -$713.4 million, down 403.27%, while the annual FY2025 figure was -$713.4 million, 403.27% down from the prior year.
  • Profit After Tax for Q4 2025 was -$412.2 million at Sarepta Therapeutics, down from -$50.6 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $196.9 million in Q2 2025 and troughed at -$516.8 million in Q1 2023.
  • A 5-year average of -$106.8 million and a median of -$66.0 million in 2021 define the central range for Profit After Tax.
  • On a YoY basis, Profit After Tax climbed as much as 2947.86% in 2025 and fell as far as 1338.98% in 2025.
  • Year by year, Profit After Tax stood at -$122.0 million in 2021, then grew by 10.44% to -$109.2 million in 2022, then skyrocketed by 141.79% to $45.7 million in 2023, then surged by 248.37% to $159.0 million in 2024, then plummeted by 359.18% to -$412.2 million in 2025.
  • Business Quant data shows Profit After Tax for SRPT at -$412.2 million in Q4 2025, -$50.6 million in Q3 2025, and $196.9 million in Q2 2025.